Floatz logo

Rindopepimut

Glioblastoma

Celldex TherapeuticsvaccinePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
65/ 100

Competitive context

354 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Rindopepimut is also rated in:

giant cell glioblastomaDormant
BB
Indicative ·
69 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
64 / 100
View asset →
malignant gliomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →